Normalizing NADPH oxidase contributes to attenuating diabetic nephropathy by the dual endothelin receptor antagonist CPU0213 in rats

American Journal of Nephrology

Volumn 29, Issue 3, 2009, Pages 252-256

  Xu, Ming ^a   Dai, De Zai ^a   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

CPU0213; Diabetic nephropathy; Endothelin 1; ETAR; ETBR; iNOS; NOX

Indexed keywords

APOCYNIN; CPU 0213; DIPHENYLIODONIUM SALT; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; GLUCOSE; NITRIC OXIDE SYNTHASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME SUBUNIT; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INCUBATION TIME; KIDNEY FUNCTION; KIDNEY MASS; MALE; MESANGIUM CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; MALE; NADPH OXIDASE; OXIDATIVE STRESS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN;

EID: 51849122365     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000157628     Document Type: Article

References (16)

1. Gill PS, Wilcox CS: NADPH oxidases in the kidney. Antioxid Redox Signal 2006;8:1597-1607.
2. Maranchie JK, Zhan Y: Nox4 is critical for hypoxia-inducible factor 2-alpha transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma. Cancer Res 2005;65:9190-9193.
3. Asaba K, Tojo A, Onozato ML, Goto A, Quinn MT, Fujita T, Wilcox CS: Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 2005;67:1890-1898.
4. Chen HC, Guh JY, Shin SJ, Tsai JH, Lai YH: Reactive oxygen species enhances endothelin-1 production of diabetic rat glomeruli in vitro and in vivo. J Lab Clin Med 2000;135:309-315.
5. Qi MY, Xia HJ, Dai DZ, Dai Y: A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats. J Cardiovasc Pharmacol 2006;47:729-735.
6. Sasser JM, Sullivan JC, Hobbs JL, Yamamoto T, Pollock DM, Carmines PK, Pollock JS: Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 2007;18:143-154.
7. Cosenzi A, Bernobich E, Trevisan R, Milutinovic N, Borri A, Bellini G: Nephroprotective effect of bosentan in diabetic rats. J Cardiovasc Pharmacol 2003;42:752-756.
8. Neuhofer W, Pittrow D: Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest 2006;36(suppl 3):78-88.
9. Dai DZ, Huang M, Ji M, Liu LG: Endothelin receptor antagonist activity and selective blocking of ETA and ETB by compound 0213 (in Chinese). J China Pharm Univ 2004;35:552-557.
10. Zhang TT, Cui B, Dai DZ, Tang XY: Pharmacological efficacy of CPU86017 on hypoxic pulmonary hypertension in rats mediated by direct inhibition of calcium channels and antioxidant action, but indirect effects on the ET-1 pathway. J Cardiovasc Pharmacol 2005;46:727-734.
11. Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, Sasaki T, Tsujioka K, Makino H, Kashihara N: NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 2005;288:F1144-F1152.
12. Na T, Dai DZ, Tang XY, Dai Y: Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017. Naunyn Schmiedebergs Arch Pharmacol 2007;375:39-49.
13. Tojo A, Asaba K, Onozato ML: Suppressing renal NADPH oxidase to treat diabetic nephropathy. Expert Opin Ther Targets 2007;11:1011-1018.
14. Dong F, Zhang X, Ren J: Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension 2006;47:222-229.
15. Lauth M, Berger MM, Cattaruzza M, Hecker M: Elevated perfusion pressure upregulates endothelin-1 and endothelin B receptor expression in the rabbit carotid artery. Hypertension 2000;35:648-654.
16. Pfab T, Thöne-Reineke C, Theilig F, Lange I, Witt H, Maser-Gluth C, Bader M, Stasch JP, Ruiz P, Bachmann S, Yanagisawa M, Hocher B: Diabetic endothelin B receptor-deficient rats develop severe hypertension and progressive renal failure. J Am Soc Nephrol 2006;17:1082-1089.